Myriad Sees No Impact On Its Business From Patent Ruling; Wall Street Cautious
This article was originally published in The Pink Sheet Daily
Executive Summary
Myriad expects new, multi-gene panels of tests, the first of which it plans to launch this fall, will eventually replace the breast and ovarian cancer tests at the heart of the June 13 Supreme Court decision, thereby diffusing the ruling’s potential impact on its business. At the same time, it says it has more than 500 “enforceable patents” protecting its breast cancer tests through 2018.